Takeda Pharmaceutical (NYSE:TAK) Hits New 12-Month High – What’s Next?

Takeda Pharmaceutical Company Limited (NYSE:TAK)’s stock price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $15.22 and last traded at $15.20, with a volume of 561724 shares. The stock had previously closed at $15.01.

Takeda Pharmaceutical Trading Up 1.1 %

The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The stock has a 50 day simple moving average of $13.76 and a 200-day simple moving average of $13.90. The firm has a market cap of $48.29 billion, a P/E ratio of 37.96, a P/E/G ratio of 0.24 and a beta of 0.46.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, equities research analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Takeda Pharmaceutical

Several large investors have recently modified their holdings of the stock. Forum Financial Management LP increased its position in shares of Takeda Pharmaceutical by 133.7% during the 4th quarter. Forum Financial Management LP now owns 114,324 shares of the company’s stock valued at $1,514,000 after purchasing an additional 65,399 shares during the last quarter. Toronto Dominion Bank bought a new position in Takeda Pharmaceutical in the 4th quarter valued at $6,760,000. GTS Securities LLC bought a new position in Takeda Pharmaceutical in the 4th quarter valued at $1,292,000. Vise Technologies Inc. grew its position in Takeda Pharmaceutical by 3.1% in the 4th quarter. Vise Technologies Inc. now owns 34,635 shares of the company’s stock valued at $459,000 after acquiring an additional 1,026 shares during the last quarter. Finally, Voloridge Investment Management LLC grew its position in Takeda Pharmaceutical by 150.6% in the 4th quarter. Voloridge Investment Management LLC now owns 340,953 shares of the company’s stock valued at $4,514,000 after acquiring an additional 204,911 shares during the last quarter. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.